POMZP3

Across TCGA pan-cancer cohorts, POMZP3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated POMZP3 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher POMZP3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated POMZP3 expression acts as an unfavorable survival marker.

MESO and UCEC are the cancer types where POMZP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	II,III,IV	0.039	0.407	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

POMZP3–MESO (DFS)

Open the MESO breakdown →